 Patent Application Title |
Patent App Num. |
Date |
| Tumour cell lines and uses thereof | 20110319590 | 20111229 |
| The present invention relates to a cell line selected from the group consisting of (a) a cell line denominated NM-F9 having the DSMZ accession number DSM ACC2606; (b) a cell line denominated NM-D4 having the DSMZ accession number DSM ACC2605; and subclones of (a) or (b). Additionally, the present invention provides a lysate of the cell lines or a molecule or mixture of molecules obtained from these cell lines as well as dendritic cells loaded with said lysate, co-cultivated or fused with cells from the cell lines, or a molecule or mixture of molecules obtained from these cell lines of the present invention. Moreover compositions, preferably pharmaceutical or vaccine compositions are provided which comprise the cell lines, lysate, molecules, mixture of molecules or dendritic cells of... |
| Mesenchymal stromal cell populations and methods of isolating and using same | 20110293576 | 20111201 |
| The invention relates to mesenchymal stromal cells produced by culturing the cells in platelet lysate supplemented media and methods of using these cells to treat neurological and kidney associated disorders.
... |
| Processing and analysis of viscous liquid biological samples | 20110281272 | 20111117 |
| The present invention provides a lysis buffer comprising a chaotropic agent and a reducing agent suitable for liquefaction of a highly viscous liquid biological sample, such as sputum, a use of said lysis buffer for the processing of a highly viscous liquid biological sample, methods for processing or analyzing a highly viscous liquid biological sample, or a method for detecting a pathogen within a highly viscous liquid biological sample. Furthermore, the present invention relates to a lysate comprising a highly viscous liquid biological sample and the lysis buffer according to the present invention, a ready-to-use reaction tube and a kit comprising the lysis buffer according to the present invention.
... |
| Platelet lysate and bioadhesive compositions thereof for the treatment of mucositis | 20110280952 | 20111117 |
| The present invention concerns the use of platelet lysate for treating and/or preventing mucositis. Moreover, a mucoadhesive composition comprising such a platelet lysate for the therapy and/or prevention of mucositis and of corneal lesions is described.
... |
| Quality of life for hepatitis c patients with a formulation for administration to the oral mucosa including lactobacillus delbrueckii subsp. bulgaricus and n-acetyl d-glucosamine | 20110268829 | 20111103 |
| Disclosed are quick dissolve tablets, each including Lactobacillus delbrueckii subsp bulgaricus (LBD) and N-acetyl-glucosamine (NAG), as well as excipients, for oral mucosal administration, for improving the quality of life of Hepatitis C patients. Any formulation suitable for oral mucosal administration can be employed for administering the active ingredients in a sufficient dosage for therapeutic effect, one such formulation being: 50 mg of Lactobacillus delbrueckii subsp bulgaricus lysate strain YB-I 10 mg of N-acetyl D-glucosamine. Excipients can include one or more of, maltodextrin; xanthan gum; acesulfam K; lemon powder and a flavoring, e.g., juice; Mannitol TL-32-04, Microcrystalline Cellulose and Carrageenan, Fructose, PVP-XL TL-11-04, Gellan Gum, Citrus TL 1-04, Orange TL 19-04, Sucrolose TL-13-04, and Mg ST TL-13-04.
... |
Subscribe to updates on this page: Lysate RSS  |
| Method of using tumor cell debris to reduce brain tumor recurrence or growth | 20110257458 | 20111020 |
| The present invention describes compositions comprising tumor cell debris, tumor lysate or tumor antigens and methods of using tumor cell debris, tumor lysate or tumor antigens for stimulating a specific immune response. The compositions may further comprise at least one TLR ligand. The stimulation of the specific immune response may be used to treat tumors, particularly, brain tumors. The treatment method may also reduce the recurrence of a tumor and/or inhibit or slow down the growth of a tumor.
... |
| Processes for making [r]-ethyl 4-cyano-3 hydroxybutyric acid | 20110250657 | 20111013 |
| The invention provides novel processes for making ethyl-4-cyano-3-hydroxybutyrate, e.g., (R)-ethyl 4-cyano-3-hydroxybutyric acid, and 4-cyano-3-hydroxybutyric acid. The invention provides protocols for making and 4-cyano-3-hydroxybutyric acid and ethyl-4-cyano-3-hydroxybutyrate by whole cell processes, cell lysate processes, “one pot processes” and “multi-pot” processes using a variety of parameters.
... |
| Methods and compositions for inhibition of treg cells | 20110250173 | 20111013 |
| The present invention relates to methods of suppressing the immune tolerance of a disease or disease antigens in a patient. The method also promotes the activity of the effector T lymphocytes. The invention includes administering a therapeutic composition that promotes a Th1 environment in the patient while decreasing the immunosuppressive activity of Treg cells that can lead to disease antigen tolerance and immunoavoidance of the disease antigens by the patient. The therapeutic composition includes allogeneic emTh-1 cells. The therapeutic composition can also include disease antigens such as the chaperone-rich cell lysate of the disease antigen.
... |
| Composition for cancer prevention or treatment containing as active ingredient plant stem cell line dervied from cambium of panax ginseng including wild ginseng or ginseng | 20110229443 | 20110922 |
| The cell line according to the present invention, a lysate thereof, an extract thereof and a culture medium thereof are derived from a natural and have minimized side effects compared to the conventional therapeutic drugs, and thus are safe for the human body. Also, they are involved directly in the growth of cancer to induce cancer cell death effectively, and show anticancer activity of inhibiting or reducing the formation of tumor or the growth of tumor, Accordingly, the cell line, the lysate thereof, the extract thereof and the culture medium thereof are useful for the prevention, treatment and alleviation of cancer.
... |
| Immunoassays for autoantibodies in cardiovascular diseases | 20110223617 | 20110915 |
| The present invention relates to the quantitative measurement of auto-reactive antibodies in a patient sample. In particular, the present invention is directed to, inter alia, a method for predicting the degree of cardiovascular injury in a patient following an ischemic event, said method comprising: immobilizing anti-NMHC II antibody on a solid support; adding a lysate of cardiac tissue to the solid support so that antigens in the lysate are captured by the immobilized antibody; adding a biological sample from the patient to said solid support, and incubating said sample for a time sufficient for IgM autoantibodies in the biological sample to bind to antigens in the cardiac tissue lysate; contacting said solid support with an anti-IgM antibody; removing unbound labeled antibodies; and determining the level of... |
| Method for measuring carbon nanotubes taken-up by a plurality of living cells | 20110203927 | 20110825 |
| The present invention provides methods, apparatuses and kits for determining the presence and the concentration of nanoparticles in a given area, solution or region via cellular uptake and/or adsorption monitored through laboratory equipment. For example, the present invention provides a method of quantifying one or more nanoparticles by incubating a nanoparticle solution comprising one or more nanoparticles with one or more cells; isolating the one or more cells; lysing the one or more cells to release a cell lysate; separating the cell lysate electrophoretically on a gel; digitizing the gel to form a gel image; quantifying the nanoparticle intensity in the gel image; and correlating the nanoparticle intensity to a cell-associated nanoparticle concentration.
... |
| Compositions for the detection of microbial contaminants | 20110201049 | 20110818 |
| The invention provides methods and compositions for the detection and/or quantification of a microbial contaminant, for example, a bacterial endotoxin or a glucan, in a sample. In particular, the invention provides a test cartridge useful in the practice of hemocyte lysate-based assays for the detection and/or quantification of a microbial contaminant in a sample. In addition, the invention provides methods of making and using such cartridges. In addition, the invention provides a rapid, sensitive, multi-step kinetic hemocyte lysate-based assay for the detection and/or quantification of a microbial contaminant in a sample. In addition, the invention provides a glucan-specific lysate that can be used in a variety of assay formats, including, for example, a test cartridge, optionally configured to perform a kinetic assay.
... |
| Compositions and methods to promote implantation and engrafment of stem cells | 20110200642 | 20110818 |
| Tissue repair in-vivo depends on acute inflammation, but in many clinical situations the other major components of healing such as blood supply, anabolic hormones, growth factors, and stem cells are lacking. This invention includes compositions consisting of an agent which induces an inflammatory healing response combined with an autologous platelet lysate at a specific concentration which may have demonstrated in-vitro abilities to expand autologous tissue repair cells.
... |
Subscribe to updates on this page: Lysate RSS |
| Method and apparatus for processing algae | 20110192792 | 20110811 |
| Methods and apparatus for processing algae are described in which a hydrophilic ionic liquid is used to lyse algae cells. The lysate separates into at least two layers including a lipid-containing hydrophobic layer and an ionic liquid-containing hydrophilic layer. A salt or salt solution may be used to remove water from the ionic liquid-containing layer before the ionic liquid is reused. The used salt may also be dried and/or concentrated and reused. The method can operate at relatively low lysis, processing, and recycling temperatures, which minimizes the environmental impact of algae processing while providing reusable biofuels and other useful products.
... |
| Expansion medium for cd34-negative stem cells | 20110183414 | 20110728 |
| This invention provides a cell growth medium comprising (a) a human platelet lysate free of solid matter greater than 0.22 μm in diameter, wherein the lysate constitutes from 2% to 15% of the total volume of the cell growth medium; (b) a human fresh frozen plasma (FFP) filtrate free of solid matter greater than 0.22 μm in diameter, wherein the FFP filtrate constitutes from 1% to 10% of the total volume of the cell growth medium; (c) heparin at a concentration of from 0 U/ml to 10 U/ml of the cell growth medium; (d) L-glutamine at a concentration of from 0.5 mM to 10 mM; and (e) a serum-free, low glucose medium suitable for mammalian cell growth, wherein the serum-free, low glucose medium constitutes from 75%... |
| Determining the sensitivity of a cell to a drug | 20110183317 | 20110728 |
| The present invention provides an in vitro method for determining the resistance or sensitivity of a cell line or patient sample to a deoxyribonucleoside kinase-dependent drug, wherein the method comprises the steps of: (i) treating a patient sample or cell line, or a portion thereof, with a deoxyribonucleoside kinase-dependent drug; (ii) lysing the cells of the patient sample or cell line from step (i); (iii) optionally, mixing a portion of the cell lysate from step (ii) with a bioluminescent reporter bacteria incorporating a gene coding for deoxyribonucleoside kinase; (iv) mixing a portion of the cell lysate from (ii) with a bioluminescent reporter bacteria incorporating a gene coding for a deoxyribonucleoside kinase and a deoxyribonucleoside kinase transcription promoter; (v) mixing a portion of the cell lysate from... |
| Rapid analytical method for mixed biological samples | 20110177516 | 20110721 |
| The present invention relates to a rapid method for the amplification of nucleic acids from biological samples which contain a mixture of different cells or a mixture of cells with contaminating components, in which such cells are lysed in a lysis solution (A) and the lysate can be used immediately subsequently for the analysis using a method amplifying nucleic acid.
... |
| Compositions containing platelet contents | 20110171731 | 20110714 |
| This document provides methods and materials relating to platelet lysates. For example, methods and materials for using platelet lysate compositions to grow adult stem cells, to differentiate adult stem cells, to grow primary cell cultures, to grow tumor stem cells, and to identify effective growth factors are provided.
... |
| Methods and devices for producing biomolecules | 20110124101 | 20110526 |
| A scalable process and device for producing a bio molecule, in particular pharmaceutical grade plasmid DNA is described. The process includes the steps of alkaline lysis, neutralization and clarification and can be further extended. For separating the lysate and the precipitate an improved floatation method is disclosed. This method is based on attachment of CO2 bubbles on the precipitate floe. The CO2 is released from a carbonate salt during or after neutralization (acidification). The method of the invention is preferably carried out in an automated continuous mode applying devices for lysis and neutralization and a novel device for completely continuous clarification (separation of floes and clarified lysate).
... |
| Mesenchymal stromal cell populations and methods of using same | 20110123498 | 20110526 |
| The invention relates to mesenchymal stromal cells produced by culturing the cells in platelet lysate supplemented media and methods of using these cells to treat neurological and kidney associated disorders.
... |
| Antioxidant, anti-inflammatory or anti-aging composition containing taxus cambium- or procambium-derived cell line as active ingredient | 20110117039 | 20110519 |
| The present invention relates to an antioxidant, anti-inflammatory or anti-aging composition containing any one or more of a Taxus cambium- or procambium-derived cell line, an extract thereof, a lysate thereof and a culture medium thereof. The composition according to the present invention has minimized side effects compared to existing antioxidants and anti-inflammatory agents, is involved in intracellular metabolism to reduce intracellular reactive oxygen species, and reduces and induces aging-related signals. Thus, the composition of the preset invention is useful for preventing and delaying aging. In addition, the composition of the present invention has the effect of inhibiting melanogenesis, and thus is useful as a whitening cosmetic composition.
... |
| Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors | 20110104210 | 20110505 |
| Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendentic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate.
... |
| Anti-aging or antioxidant composition containing plant stem cell line derived from cambium of panax ginseng | 20110097310 | 20110428 |
| The present invention relates to an anti-aging or antioxidant composition which contains, as an active ingredient, a plant stem cell line derived from the cambium of Panax ginseng, including wild ginseng and ginseng, or an extract thereof, a lysate thereof and a culture thereof. The composition has minimized side effects compared to existing anti-aging agents and antioxidants, and thus is safe for the skin. Also, the composition of the present invention shows an antioxidant effect of inhibiting reactive oxygen species caused by exposure to UV radiation that is the major cause of skin aging, and it can effectively reduce or inhibit aging-related factors. Thus, the composition is useful for the prevention and inhibition of aging.
... |
| Apparatus and method for preparative scale purification of nucleic acids | 20110070638 | 20110324 |
| Apparatus and methods are described for pharmaceutical grade manufacture extrachromosomal nucleic acids from cell lysates using flotation to separate and eliminate undesired insoluble cellular debris including chromosomal DNA from the lysates. A gas is introduced to controllably generate bubbles that reduce the density of the cell debris and create a buoyant flocculent phase that can be readily separated from, and thus provide, a substantially clarified fluid lysate phase that is enriched in extrachromosomal DNA but substantially depleted of cellular proteins and chromosomal DNA.
... |
| Method for producing corn gluten hydrolysate and corn gluten hydrolysate using the same | 20110070608 | 20110324 |
| Provided is a method for producing corn gluten hydrolysate comprising: (a) separating corn gluten protein by removing carbohydrate, water soluble sugars, inorganic materials and fiber material; (b) preparing corn gluten protein lysate by carrying out acid hydrolysis, enzymatic hydrolysis or natural fermentation; and (c) increasing a content of branch chain amino acid (BCAA) which is included in the hydrolysate by isolating, concentrating, precipitating, desalting and filtering the resultant corn gluten protein lysate. With improved pre-treatment and concentration processes as compared with the conventional method, the hydrolysate prepared according to the present invention is rich in amino acids and low-molecular-weight peptides. In particular, free amino acids and branched-chain amino acids (BCAA) are included in large quantity.
... |
| Selective purification of small rnas from mixtures | 20110060135 | 20110310 |
| Methods and kits are provided for obtaining small RNAs from a mixture of RNAs of varying sizes such as can be found in a cell lysate or an enzyme-digested RNA. The methods and kits utilize magnetic beads and require the addition of one or more alcohols to bind small RNAs effectively to the beads.
... |
| Molecule detecting system | 20110059859 | 20110310 |
| The invention disclosed here has several key elements: direct probe-on-sensor detection, mesh probe, and mesh reporter. Furthermore, the mesh probe and reporter shall have some physical cross-linking between the polymer backbone(s), either covalently or non-covalently. In combination, this invention enables one to build an ultra-sensitive, low-cost, and highly portable system for molecular detection. Among its many potential applications is a direct detection of nucleic acids in crude lysate in a multiplex format, without the requirements for nucleic acids extraction and amplification. Such an improvement is likely to change the practice of genotyping and gene expression profiling done in a clinic setting. Another application is an ultrasensitive ELIZA assay in a multiplex format.
... |
| Probes and methods for detection of pathogens and antibiotic resistance | 20110027782 | 20110203 |
| Described are probes and methods for detecting pathogens and antibiotic resistance of a specimen. The method comprises contacting the specimen with a growth medium; and lysing the specimen to release nucleic acid molecules from the specimen. The lysate of the specimen is contacted with a capture probe immobilized on a substrate, wherein the capture probe comprises an oligonucleotide that specifically hybridizes with a first target nucleic acid sequence region of ribosomal RNA. The lysate is in contact with a detector probe that comprises a detectably labeled oligonucleotide that specifically hybridizes with a second target nucleic acid sequence region of ribosomal RNA. The presence or absence of labeled oligonucleotide complexed with the substrate is determined. Detection of labeled oligonucleotide complexed with the substrate is indicative of the... |
| Method for generating primate cardiovascular progenitor cells for clinical use from primate embryonic stem cells or embryonic-like state cells, and their applications | 20110014691 | 20110120 |
| The present invention is directed to a method for the in vitro preparation of cardiovascular progenitors cells from mammalian embryonic stem cells (ES cells) or mammalian embryonic-like state cells, preferably from primate, wherein said method comprises the use of the CD15 (SSEAI) marker as a positive cardiovascular progenitors differentiation marker. The present invention also claimed the use of a receptor tyrosine kinase inhibitor, particularly the SU5402 or SU11248 in association with the BMP2 for improving the efficiency of the desired differentiation. The present invention is also directed to the use of platelet lysate as foetal animal serum substitute in a culture medium intended to the proliferation or propagation of primate ES cells maintaining their pluripotency feature. Derived compositions or kits in relation with the claimed methods... |
| Purified bacteriophage, its preparation and application | 20110008873 | 20110113 |
| A method of preparation of purified bacteriophage with increased antibacterial activity, in which from bacterial lysate of phages is obtained, advantageously in the presence of lysozyme, chelating factor and detergent, in a continuous manner with ultrafiltration on membranes, the phage containing high molecular mass preparation, devoid of bacterial cell wall and other contaminants, free of toxins and endotoxins, active in tests of bacterial lysis, which is characterized by chromatography HPLC, In SDS-PAGE electrophoresis, immunoblotting, biological tests of bacterial lysis, and is dedicated for phage therapy of bacterial infections and tumors and for production of phage deriving pharmaceutical preparations.
... |
| Method for generating primate cardiovascular progenitor cells for clinical use from primate embryonic stem cells or embryonic-like state cells, and their applications | 20110014691 | 20110120 |
| The present invention is directed to a method for the in vitro preparation of cardiovascular progenitors cells from mammalian embryonic stem cells (ES cells) or mammalian embryonic-like state cells, preferably from primate, wherein said method comprises the use of the CD15 (SSEAI) marker as a positive cardiovascular progenitors differentiation marker. The present invention also claimed the use of a receptor tyrosine kinase inhibitor, particularly the SU5402 or SU11248 in association with the BMP2 for improving the efficiency of the desired differentiation. The present invention is also directed to the use of platelet lysate as foetal animal serum substitute in a culture medium intended to the proliferation or propagation of primate ES cells maintaining their pluripotency feature. Derived compositions or kits in relation with the claimed methods... |
| Method for producing an l-amino acid | 20110014663 | 20110120 |
| An L-amino acid is produced by culturing a bacterium having an L-amino acid-producing ability in a medium containing a processed product of a microalga which promotes production and accumulation of the L-amino acid by the bacterium. The process product is produced by disrupting the culture of the microalga, and/or extracting the culture of the microalga, or fractionating the culture of the microalga or the disrupted culture. The processed product contains a mixture of organic substances produced by the microalga, a hydrolysate of the disrupted microalga culture, and/or an extract or fractionation product of the microalga culture. The processed product can also contain a saccarification product of starch or a hydrolysate of fats and oils. The bacterium is cultured to produce and accumulate the L-amino acid in... |
| Rna interference mediating small rna molecules | 20110014123 | 20110120 |
| Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3′ ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
... |
| Peritoneal dialysis therapy with large dialysis solution volumes | 20110009810 | 20110113 |
| Patients suffering from acute renal failure must be diagnosed and treated quickly so that a physician can confidently prescribe either peritoneal dialysis or hemodialysis. In one way of quickly treating the patients, software is used to calculate a suitable peritoneal dialysis prescription without regard to how short or how long a dialysis cycle is used, and without regard to a total dialysate fluid volume for a therapy. For patients with suitable peritoneal membrane transport properties, the software program suggests that, at least over a short period of time, unexpectedly high ultrafiltrate volumes and high clearances may be achieved.
... |
| Dialysis system including blood and dialysate cassette | 20110009797 | 20110113 |
| A dialysis system including a dialysis machine including a blood pump actuator, dialysate pump actuator, a blood valve actuator and a dialysate valve actuator; and a disposable cassette operable with the dialysis machine, the disposable cassette including: (i) a housing, (ii) a dialysate pump portion of the housing configured to operate with the dialysate pump actuator, (iii) a blood valve portion of the housing configured to operate with the blood valve actuator, (iv) a dialysate valve portion of the housing configured to operate with the dialysate valve actuator, (v) a dialyzer supported by the housing, the dialyzer including a dialysate inlet and a dialysate outlet, (vi) a first dialysate connection extending externally from the housing to the dialyzer inlet, and (vii) a second dialysate connection extending... |
| Purified bacteriophage, its preparation and application | 20110008873 | 20110113 |
| A method of preparation of purified bacteriophage with increased antibacterial activity, in which from bacterial lysate of phages is obtained, advantageously in the presence of lysozyme, chelating factor and detergent, in a continuous manner with ultrafiltration on membranes, the phage containing high molecular mass preparation, devoid of bacterial cell wall and other contaminants, free of toxins and endotoxins, active in tests of bacterial lysis, which is characterized by chromatography HPLC, In SDS-PAGE electrophoresis, immunoblotting, biological tests of bacterial lysis, and is dedicated for phage therapy of bacterial infections and tumors and for production of phage deriving pharmaceutical preparations.
... |
| Dialysis system with balance chamber prime and rinseback | 20110005992 | 20110113 |
| A dialysis system includes an extracorporeal circuit including a dialyzer; a dialysis fluid circuit including a first balance chamber, a second balance chamber, a fresh dialysis fluid pump in fluid communication with first and second fresh compartments of the first and second balance chambers, respectively, the first and second fresh compartments in fluid communication with a fresh dialysate fluid inlet of the dialyzer, and a spent dialysis fluid pump in fluid communication with first and second spent compartments of the first and second balance chambers, respectively, the spent dialysis fluid pump also in fluid communication with a spent dialysis fluid outlet of the dialyzer; and wherein the system is configured to run a priming sequence that uses (i) at least one of the fresh and spent... |
| Methods, kits and compositions for the identification of nucleic acids electrostatically bound to matrices | 20110003712 | 20110106 |
| This invention pertains to methods, kits and compositions suitable for the detection, identification and/or quantitation of nucleic acids which are electrostatically immobilized to matrices using non-nucleotide probes which sequence specifically hybridize to one or more target sequences of the nucleic acid but do not otherwise substantially interact with the matrix. Once the nucleic acid is immobilized, the detectable non-nucleotide probe/target sequence complex, formed before or after the immobilization of the nucleic acid, can be detected, identified or quantitated under a wide range of assay conditions as a means to detect, identify or quantitate the target sequence in the sample. Because it is reversibly bound, the non-nucleotide probe/target sequence can optionally be removed from the matrix for detecting, identifying or quantitating the target sequence in the sample.... |
| Capture purification processes for proteins expressed in a non-mammalian system | 20100331526 | 20101230 |
| Methods of purifying proteins expressed in non-mammalian expression systems in a non-native soluble form directly from cell lysate are disclosed. Methods of purifying proteins expressed in non-mammalian expression systems in a non-native limited solubility form directly from a refold solution are also disclosed. Resin regeneration methods are also provided.
... |
| Substrate for assaying beta-glucan and/or endotoxin and assay method | 20100330700 | 20101230 |
| is separated from unreacted substance and quantified, and the determination is made based on this value, and (4) a reagent kit for determining β-glucan and/or endotoxin, comprising an amebocyte lysate of a horseshoe crab and the above-described peptide derivative as constituents thereof.
... |
| Heat-treated limulus amebocyte lysates | 20100330597 | 20101230 |
| The application provides heat-treated Limulus amebocyte lysates useful for detecting β-glucans.
... |
| Non-digestible hydroxypropyl starch hydrolysate, method for production thereof and food and beverage | 20100330257 | 20101230 |
| The present invention provides a non-digestible hydroxypropyl starch hydrolysate which can be used as novel water soluble dietary fiber, a method for producing it, as well as food products and beverages containing the non-digestible hydroxypropyl starch hydrolysate. The present invention provides the non-digestible hydroxypropyl starch hydrolysate characterized by having a DE value of less than 20 and a glucose content of less than 3% by mass; food products and beverages containing it; and the method for producing the non-digestible hydroxypropyl starch hydrolysate comprising the steps of: (A) hydrolyzing a hydroxypropyl starch with a degree of substitution of 0.05 to 0.4 with α-amylase and then with glucoamylase; and (B) removing glucose from the hydrolysate obtained in the step (A).
... |
| Dialysis system | 20100326916 | 20101230 |
| A dialysis system includes a filtration system capable of filtering a water stream, a water purification system capable of purifying said water stream in a non-batch process, a mixing system capable of producing a stream of dialysate from mixing one or more dialysate components with the water stream in a non-batch process, and a dialyzer system. The dialyzer may be a microfluidic dialyzer capable of being fluidly coupled to the stream of dialysate and a blood stream.
... |
| Dialysis system | 20100326911 | 20101230 |
| A dialysate fluid circulation apparatus includes a dialyzer, a first housing and a second housing. The first housing contains material capable of releasing sodium into dialysate fluid flowing through the first housing. The second housing contains material capable of binding sodium ions from dialysate fluid flowing through the second housing. Hydraulic conduit sections are configured to extend between the dialyzer, the first housing, and the second housing to connect the dialyzer with the housings in a primary flow path for dialysate fluid to flow from the dialyzer to the first housing, from the first housing to the second housing, and from the second housing back to the dialyzer.
... |
| Hydrolysates made of plant extracts and antibacterial agent containing the same | 20100323013 | 20101223 |
| The present invention relates to an antibacterial agent and a hydrolysate made of at least one extract that has been produced by extraction using ethanol/water from dried plant material of: a) at least one of the plants selected from the group consisting of: Verbena officinalis L., Sambucus nigra L., Primula veris L., Primula elatior (L.) Hill, and Gentiana lutea L.; and a mixture thereof; or b) a mixture of: Verbena officinalis L., Sambucus nigra L., Primula veris L., Gentiana lutea L., and Rumicis herba; and subsequent removal of the ethanol/water extraction agent, wherein the hydrolysate can be obtained from the extract via hydrolytic treatment using a mineral acid. The hydrolyzates according to the invention show a pronounced antibacterial effect against germs relevant to the skin, ears,... |
| Use of a cruciferous protein hydrolysate as a depigmentation agent or for a cosmetic and/or pharmaceutical composition | 20100322886 | 20101223 |
| Method for skin bleaching or depigmentation using an effective amount of a protein hydrolysate from plants belonging to the cruciferous family.
... |
| Methods, compositions and uses for enhancing chemical tolerance by microorganisms | 20100317115 | 20101216 |
| Embodiments herein concern compositions and methods for enhancing chemical tolerance of biomass conversion by microorganisms. In some embodiments, enhancing tolerance of biomass hydrolysate conversion includes enhancing tolerance to low molecular weight organic compounds.
... |
| Systems and methods for extracting lipids from wet algal biomass | 20100317088 | 20101216 |
| Presented herein are exemplary systems and methods for extracting lipids from a wet algal biomass. An exemplary method comprises lysing a wet algal biomass with an insoluble granular lysing agent to create a lysate, creating a lipid-rich phase in the lysate, and separating the lipid-rich phase from the lysate. An exemplary system comprises a lysing station for creating a lysate from a wet algal biomass and a separation station for creating and separating a lipid-rich phase from the lysate. According to further exemplary systems and methods, ultrasound may be used in place of or in addition to a lysing agent to lyse the wet algal biomass.
... |
| Siloxane-based resin composition | 20100316953 | 20101216 |
| The present invention is a siloxane-based resin composition including a siloxane-based resin and an imidosilane compound having a specific structure. Moreover, the present invention is a siloxane-based resin composition including a siloxane-based resin which is a reactive product to be obtained by hydrolyzing an alkoxysilane compound and an imidosilane compound having a specific structure and then making the resulting hydrolysate undergo a condensation reaction. According to the present invention, it is possible to form a cured film excellent in adhesion.
... |
| Rna interference mediating small rna molecules | 20100316703 | 20101216 |
| Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3′ ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
... |
| Peritoneal dialysis system | 20100312174 | 20101209 |
| The present invention is a sorbent-based portable peritoneal dialysis system that uses 2.5 liters of tap water per day. The system comprises a control unit, a sterilized disposable cassette, a sterilized disposable glucose solution cartridge and a sterilized sorbent cartridge, and a three liter removable fluid storage container. A supply of concentrated electrolytes solution and a venting sterilizing dialysate filter are contained in the cassette. The glucose and sorbent cartridges snap into the cassette, which snaps onto the control unit. The cartridges are replaced daily, and the cassette is replaced weekly. During use (typically while the patient sleeps at night), the system removes all spent dialysate from the patient every two hours. The system then returns two liters of regenerated, sterilized dialysate to the patient. The... |
| Method of peritoneal dialysis | 20100312172 | 20101209 |
| The present invention is a sorbent-based portable peritoneal dialysis system that uses 2.5 liters of tap water per day. The system comprises a control unit, a sterilized disposable cassette, a sterilized disposable glucose solution cartridge and a sterilized sorbent cartridge, and a three liter fluid storage container. A supply of concentrated electrolytes solution and a venting sterilizing dialysate filter are contained in the cassette. The glucose and sorbent cartridges snap into the cassette, which snaps onto the control unit. The cartridges are replaced daily, and the cassette is replaced weekly. During use (typically while the patient sleeps at night), the system removes all spent dialysate from the patient every two hours. The system then returns two liters of regenerated, sterilized dialysate to the patient. The patient... |
| Blood dialysis apparatus | 20100312162 | 20101209 |
| Provided is a hemodialysis apparatus which can fundamentally solve a problem in that air is trapped in a mesh disposed in a vein side chamber during priming. A hemodialysis apparatus includes control means that conducts, in the stated order: (A) a process in which a blood pump reversely rotates at the same speed as a reverse filtration speed made by third fluid feeding means, and a dialysate flows in a flow passage extending from a connection portion between a hemodialyzer and an artery side blood line to a vein side chamber through the joint portion in a loop formed by connecting the artery side blood line and the vein side blood line, to thereby prime the flow passage and the hemodialyzer, and (B) a process in... |
| Catalyst for producing polyester and method for producing polyester | 20100305296 | 20101202 |
| The invention relates to an improved linear microdialysis probe comprising a continuous length of flexible tubing (1) having at least one window (4) formed therein, said window covering at least one pan of the circumference of the tubing, while the remaining part forms at least one unbroken connection between a first end of said tubing and a second end of said tubing, said ends adapted to be attached to an inlet for perfusion liquid and the other end forming an outlet for the dialysate, said at least one window (4) exposing a tubular semipermeable membrane (2).
... |
| Protein product with modified antigenicity | 20100305050 | 20101202 |
| A bovine casein protein hydrolysate prepared using an enzyme having broad spectrum endopeptidase activity has low residual antigenicity properties in mammals compared to intact casein protein, The composition is useful as an ingredient in foods, beverages, pharmaceutical and cosmetic products. A hydrolysate prepared using Alcalase™ with a degree of hydrolysis of 19.88% has very desirably low antigenicity characteristics.
... |
| Bioreactor for mesophilic and/or thermophilic fermentation | 20100304420 | 20101202 |
| This invention relates to a bioreactor for producing high rates of hydrogen from plant biomass. It also relates to the rapid screening, selection and isolation of biofilm forming mesophilic and/or thermophilic bacteria or bacteria consortia that generate high levels of hydrogen from plant biomass or from soluble hydrolysates derived from the hydrolysis of cellulosic materials including hemicellulose. The reactor comprises a primary reactor vessel having a bed of hydrogen producing bacteria towards its base located within a secondary reactor vessel which functions as a hydrogen gas collector and as a clarifier and separator. The plant biomass may be one or a mixture of insoluble cellulosic material and a hydrolysate derived from hydrolysis of cellulosic material. In one embodiment the bed of the primary reactor vessel is... |
| Method for the determination of at least one characteristic figure relating to a patient's glucose metabolism, and apparatus therefor | 20100298751 | 20101125 |
| The present invention relates to a method for detecting at least one characteristic relating to a patient's glucose metabolism, having steps to be performed during an extracorporeal treatment of the patient's blood, particularly during a dialysis treatment, of the extracorporeal addition of glucose and/or insulin and extracorporeal measurement of a glucose concentration and/or an insulin concentration. The invention further proposes a corresponding device. In addition, the invention proposes a method for determining the composition of the dialysate for the extracorporeal treatment of a patient's blood having the steps of determining a glucose level in the patient's blood during the dialysis session and adapting the amount of glucose added to the dialysate or blood based on the glucose level determined. To this end, the invention proposes a... |
| Method of producing alcohol in the biorefinery context | 20100297717 | 20101125 |
| 3) alcoholic fermentation by a suitable alcohol-producing microorganism of the hydrolysate from stage (2) until a fermentation must is obtained, and separation of the alcohol-producing microorganism used in stage (3), separation/purification of the alcohol.
... |
| Treatment of diabetes with milk protein hydrolysate | 20100297253 | 20101125 |
| A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum.
... |
| Rna interference mediating small rna molecules | 20100292456 | 20101118 |
| Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAI. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3′ ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
... |
| Process for concentrating and processing fluid samples | 20090326211 | 20091231 |
| A method of treating a liquid sample having microbiological target species therein to concentrate the species and collect lysate is disclosed. The liquid sample comprises non-target microbiological particles, inorganic particles, and microbiological target species. The liquid is passed through a prefilter medium to allow the target species to pass through as filtrate and retain non-target microbiological products and inorganic particles thereon. The filtrate is contacted with a main filtration medium adapted to retain the target species thereon as retentate. The retentate is lysed to form a lysate containing target material that was enveloped within the microbiological target species. The microbiological species may comprise cell containing or viral material. Target materials comprise intracellular nucleic acids, or in the case of viral sampling, nucleic acids encased within the... |
| Nucleic acid sample preparation by exclusion of dna | 20090325272 | 20091231 |
| Devices and methods are provided for separation of nucleic acids from waste materials in a biological sample, and then reacting the separated nucleic acids. In some embodiments, the methods comprise mixing a cell lysate having nucleic acids and waste materials with a waste-binding matrix to capture the cellular waste materials from the lysate. The waste-binding matrix can comprise hydrophilic and/or hydrophobic size-exclusion, ion-exchange particles. In some embodiments, the device comprises a substrate comprising a fluid processing pathway in which nucleic acid sample preparation occurs prior to a downstream genotyping reaction.
... |
| Bacteria/rna extraction device | 20090325269 | 20091231 |
| Apparatus and method for collection of a target material from a liquid sample comprising target species that contain the target material. The apparatus comprises a fluid flow conduit in communication with a filter medium having a pore size adapted to retain target species thereon and pass, as filtrate, lysate containing the desired target material. A lysing agent conduit communicates with the fluid flow conduit and delivers lysing agent to the filter medium to lyse the target cells thereby releasing the desired intracellular target material. The lysing agent may be recirculated through the filter medium for a sufficient time to permit sufficient quantity of lysate to circulate through the system for lysate collection and subsequent assay.
... |
| Vascularization enhanced graft constructs | 20090324681 | 20091231 |
| A tissue graft construct for use in repairing diseased or damaged tissues is provided. The tissue graft construct comprises a matrix composition selected from the group consisting of liver basement membrane and extracts and hydrolysates thereof, and processed collagen from vertebrate non-submucosal sources, added endothelial cells, and at least one additional preselected, exogenous population of cells which enhance the initiation of vessel-like structures in the grant. The preselected population of cells can be a population of non-keratinized or keratinized epithelial cells or a population of mesodermally derived cells selected from the group consisting of fibroblasts, smooth muscle cells, skeletal muscle cells, cardiac muscle cells, multi-potential progenitor cells, pericytes, osteogenic cells, and any other suitable cell type, preferably selected based on the tissue to be repaired. Methods... |
| Method for the production of hydrolyzed allergen | 20090324650 | 20091231 |
| b) purifying said allergen hydrolysate to remove peptides with a molecular weight above 10,000 Da and below 1,000 Da in order to obtain a purified hydrolysate where 70%, more preferably 80% of the peptides are between 10,000 Da and 1,000 Da.
... |
| Hydrosilylation method | 20090318724 | 20091224 |
| Compounds containing carbon-carbon double bonds and/or carbon-carbon triple bonds are hydrosilylated with linear organopolysiloxanes having diorganosiloxy units and Si—H groups, produced by reacting diorganodichlorosilanes and monochlorosilanes and optionally dichlorosilanes with water in a first step, where at least one of the monochlorosilanes or dichlorosilanes contain Si—H groups to give a partial hydrolysate and gaseous hydrogen chloride, and in a second step, treating the partial hydrolysate with water to remove SiCl groups still present to form hydrochloric acid, and producing a hydrolysate containing the organopolysiloxanes.
... |
| Cholesterol lowering protein hydrolysates | 20090318366 | 20091224 |
| The present invention relates to the production of novel peptides which have a length of between 4 and 8 amino acids and comprises the amino acid sequence -Xaa-Xbb-Xcc-Xdd- or -Xbb-Xcc-Xdd-Xaa-, whereby Xaa and Xcc can be His (H), Arg (R) or Lys (K), and Xbb and Xdd can be Pro (P) or Gly (G).
... |
| Low sodium, high calcium, protein hydrolysate flavor enhancer and a method prepare thereof | 20090317510 | 20091224 |
| A method to produce flavor enhancer comprises the steps of hydrolyzing protein source in presence of catalysts at an operating temperature of 25° C. to 60° C. and pH 4 to 8 to form hydrolysate; or using strong acid on defatted protein source at high temperature above 95° C.; maintaining the pH of the hydrolyzing process; deactivating the catalysts in the hydrolysate; adjusting pH of the hydrolysate to 3.5-4.5 with calcium carbonate or acid; and filtering the hydrolysate through layers of activated carbon and/or calcium carbonate to obtain the flavor enhancer.
... |
| Colorimetric method and relative device for bacterial load detection | 20090311740 | 20091217 |
| A method for detecting a bacterial load comprising adding a sample for analysis to an analysis reagent in a sterilized reaction container, thermostatting the reaction container at a temperature of between 25 and 45° C., and verifying the change in colouring of the analysis reagent. The analysis reagent is an aqueous solution comprising amino acids chosen from the group consisting of meat peptones, vegetable peptones, casein hydrolysates, tryptose, tryptones and yeast extract; glucides chosen from monometric or oligomeric glucides metabolisable by micro-organisms; a buffer system suitable for maintaining the pH between 5.5 and 8.5; a redox indicator with potential between −250 and +250 mV and/or a pH indicator with colour change interval between pH 4.0 and pH 9.0; and a water-immiscible organic liquid compound having a... |
| Plastic lens | 20090311536 | 20091217 |
| A plastic lens is provided which is excellent in abrasion resistance, transparency and appearance, and the plastic lens contains, as a substrate, a lens containing a resin having an NHCO structure and a resin containing a specific monomer, and a cured film having an NHCO structure formed by reacting a coating composition directly on the substrate, the coating composition containing a component (i) that is at least one selected from a specific organosilicon compound and a hydrolysate thereof, a component (ii) that is at least one selected from an amino group-containing organic compound, a hydroxyl group-containing organic compound, a mercapto group-containing organic compound, an amino group-containing organosilicon compound, a hydroxyl group-containing organosilicon compound and a mercapto group-containing organosilicon compound, and a component (iii) that is at... |
| Iron metabolism-improving agent | 20090306002 | 20091210 |
| An acetic acid- and/or acetate salt-free iron metabolism-improving agent that contains citric acid and/or a citrate salt as electrolytes and also contains another/other electrolyte/electrolytes and glucose solely or in combination is provided. The iron metabolism-improving agent can be formulated into a dialysate and/or a substitution fluid. A method for improving internal iron metabolism and a blood purification method including hemodialysis and hemodiafiltration in a chronic renal failure patient employing the dialysate and/or the substitution fluid are further provided.
... |
| Novel nutraceutical compositions | 20090305945 | 20091210 |
| The present invention describes a composition which comprises a protein hydrolysate or a protein hydrolysate and one amino acid hydrolysate for the long term treatment or prevention of type 2 diabetes or pre-diabetes or metabolic syndrome or obesity.
... |
| Plasma-free platelet lysate for use as a supplement in cell cultures and for the preparation of cell therapeutics | 20090305401 | 20091210 |
| The present invention provides a cell culture medium supplement comprising plasma-free platelet lysate and medium supplemented with this supplement. The present invention further provides a method for preparing the supplement comprising the steps of (a) preparing platelet rich plasma; (b) removing the plasma; and (c) lysing the platelets.
... |
| Starch process | 20090305361 | 20091210 |
| The present invention relates to a process for enzymatic hydrolysis of granular starch into a soluble starch hydrolysate at a temperature below the initial gelatinization temperature of said granular starch.
... |
| Chlamydia trachomatis antigens for vaccine and diagnostic use | 20090304722 | 20091210 |
| The present invention is related to antigens from Chlamydia trachomatis which are recognized by specific antibodies from individuals infected with Chlamydia or which can induce T cells from the same individuals to secrete gamma-interferon. The T cell reactive antigens are present in a whole-cell lysate and have apparent molecular weights of 5-12, 16-20, 25-35 and 58-74 kDa as determined by SDS-PAGE. The antigens of the invention are useful in vaccines but also as diagnostic compositions.
... |
| Intradialytic administration of sodium thiosulfate | 20090304600 | 20091210 |
| The invention provides a source of sodium thiosulfate via the dialysate used to cleanse the blood of toxic and metabolic waste in patients undergoing hemodialysis, peritoneal dialysis, or gastrointestinal dialysis for treatment of end-stage or near end-stage chronic renal disease. In the method of the invention, dialysis solution components contain therapeutic amounts of sodium thiosulfate, which when fully reconstituted for use as a single solution, deliver 20-130 mg/dl of dialysate.
... |
| Remote exchange peritoneal dialysis | 20090299273 | 20091203 |
| A portable, flexible peritoneal dialysis system is disclosed. The system includes a flexible harness, such as canvas or cloth, to mount a stiff housing with a heater for holding and heating fresh dialysis fluid. The harness includes straps or other suspending devices for holding a second, flexible housing for a drain bag for holding sent dialysis fluid. The upper portion of the system includes a hook and a load cell for suspending the remaining portions. The load cell is used to measure the weight of the apparatus. By keeping track of the weight and the changes, the quantity of fluid removed from the patient, spent dialysate, is tracked, as is fresh dialysate infused into the patient. An electronics or control portion controls heating of the fresh... |
| Agent for preventing arteriosclerosis, agent for suppressing vascular intimal thickening and agent for improving vascular endothelial function | 20090299036 | 20091203 |
| There is provided an agent having at least one of an improving effect on vascular endothelial functions and an inhibitory effect on vascular intimal thickening, as well as a prophylactic of arteriosclerosis, which have excellent safety, improve functions associated with the vascular endothelium, have effects of preventing various diseases associated with vascular endothelial functions and of inhibiting vascular intimal thickening, and may be expected to provide prophylactic effect on arteriosclerosis or the like. The agents of the present invention contain, as an active component: (a) Xaa-Pro-Pro, (b) a hydrolysate of animal milk casein containing Xaa-Pro-Pro, or a concentrate thereof, or (c) a fermentation product containing Ile-Pro-Pro and/or Val-Pro-Pro obtained by fermenting a starting material containing milk protein with a bacterial strain of the species Lactobacillus helveticus.
... |
| Formulation comprising whey protein and hydrolysates for improving muscle recovery | 20090298767 | 20091203 |
| The present invention relates to a formulation comprising whey protein or a hydrolysate of whey protein, which formulation is capable of inhibiting the expression of TNFα in lipopolysaccharide-stimulated macrophages in vitro. Also provided are uses of the formulation for attenuating a reduction in muscle function which results from muscle damage and/or for enhancing recovery from muscle damage and/or for enhancing the force generating capacity of muscle and methods of making the formulation.
... |
| Peptidylarginine deiminase and uses thereof in the production of citrullinated proteins and peptides | 20090297689 | 20091203 |
| The present invention relates to a protein, peptide or protein hydrolysate wherein the molar ratio of citrulline and arginine residues, being part of protein or peptide, is at least 0.15, preferably at least 0.30, more preferably at least 0.5, still more preferably at least 1.0, even still more preferably 2.0 and most preferably at least 4.
... |
| Method for vaccination of poultry by bacteriophage lysate bacterin | 20090297561 | 20091203 |
| Method of vaccination comprising administering to an animal in need of immunization an amount of phage lysate bacterin to induce an immune response.
... |
| Dialysis preparation | 20090294360 | 20091203 |
| The present invention provides a pharmaceutical composition for dialysis wherein the decline of ionized calcium concentration in an acetate-free bicarbonate dialysate comprising no acetic acid and/or sodium acetate is controlled. The present invention further provides a dialysis agent A that comprises electrolytes, citric acid and/or citrate as pH adjuster, and/or glucose, for preparation of bicarbonate dialysates; the agent A characterized by being adjusted by citric acid and/or citrate so as to keep the electrolyte ionized calcium concentration not less than 1 mmol/L in a prepared bicarbonate dialysate. In a specific aspect of the present invention, sodium citrate is used as citrate, and the present invention provides a dialysate obtained from above.
... |
| Customizable personal dialysis device having ease of use and therapy enhancement features | 20090294339 | 20091203 |
| A peritoneal dialysis machine includes an enclosure; dialysate pump located within the enclosure; a graphical user interface connected to the enclosure and configured to display a parameter associated with the dialysate pump; and a projector configured to project the parameter onto a surface external from the enclosure so as to allow a patient to readily view the parameter.
... |
| Enzymatic digestion of tissue | 20090286304 | 20091119 |
| The present invention concerns a compositions and method for isolating a nucleic acid from a cell-containing sample. There is disclosed a method comprising obtaining at least one cell-containing sample, which comprises a cell containing nucleic acid, obtaining at least one catabolic enzyme, obtaining at least one nuclease inhibitor, preparing an admixture of the sample, the catabolic enzyme, and the nuclease inhibitor, maintaining the admixture under conditions where the catabolic enzyme is active, and agitating the admixture, where the sample is digested to produce a nucleic acid-containing lysate of the sample.
... |
| Free-flowing gelatin composition | 20090285963 | 20091119 |
| In order to provide a novel free-flowing gelatin composition, in particular for use as food precursor, which gelatin composition retains its flowability, in particular even at temperatures below 30° C., it is proposed that the free-flowing gelatin composition comprises an aqueous liquid, gelatin gel particles dispersed therein and/or dissolved gelatin hydrolysate and one or more sugar components, wherein the sum of the contents of gelatin, gelatin hydrolysate and sugar components(s) is selected such that the water activity (aw value) of the composition is less than or equal to 0.97.
... |
| Carbon dioxide gas removal from a fluid circuit of a dialysis device | 20090282980 | 20091119 |
| The present invention is directed to degassing devices for dialysate circuits. One embodiment has a first housing and a second housing positioned within the first housing in an annular relationship. A second embodiment comprises a dialysate regeneration system with urease, a dialyzer, and a housing with an external wall, where the external wall is exposed to atmosphere and comprises a material that passes gas but does not pass liquid and where the housing is positioned between the urease and dialyzer.
... |
| Beta-xylosidase for conversion of plant cell wall carbohydrates to simple sugars | 20090280541 | 20091112 |
| Xylose-containing plant material may be hydrolyzed to xylose using a β-D-xylosidase which exhibits unexpectedly high activity. The enzyme has a kcat value for catalysis of approximately 185 sec−1 for 1,4-β-D-xylobiose (X2) when measured at a pH of 5.3 and a temperature of 25° C.; this is at least 10-fold greater than reported for other xylosidases at 25° C. and their optimal pH. The enzyme also has an isoelectric point of approximately 4.4. When reacted at a pH between about 4.5 and about 7.7, the β-D-xylosidase exhibits surprisingly high activity for hydrolyzing xylose-containing plant materials to xylose. The xylose released from plant materials may then be converted to other secondary products such as ethanol by fermentation or other reaction. This β-D-xylosidase may be used alone or in... |
| Beta-xylosidase for conversion of plant cell wall carbohydrates to simple sugars | 20090280541 | 20091112 |
| Xylose-containing plant material may be hydrolyzed to xylose using a β-D-xylosidase which exhibits unexpectedly high activity. The enzyme has a kcat value for catalysis of approximately 185 sec−1 for 1,4-β-D-xylobiose (X2) when measured at a pH of 5.3 and a temperature of 25° C.; this is at least 10-fold greater than reported for other xylosidases at 25° C. and their optimal pH. The enzyme also has an isoelectric point of approximately 4.4. When reacted at a pH between about 4.5 and about 7.7, the β-D-xylosidase exhibits surprisingly high activity for hydrolyzing xylose-containing plant materials to xylose. The xylose released from plant materials may then be converted to other secondary products such as ethanol by fermentation or other reaction. This β-D-xylosidase may be used alone or in... |
| Weight sensor and balance controller | 20090276099 | 20091105 |
| A weight sensor includes an arm having an end fixed to a pillar and a free end; a filtrate holder, a replacement fluid holder, and a dialysate holder provided at three locations of the arm along a longitudinal direction of the arm to hold respective substances; a first strain value sensor, a second strain value sensor, and a third strain value sensor each of which detects a strain value of the arm corresponding to a total weight of the substances held by the holders ranging from a holder proximate to the free end to a corresponding holder; and a weight calculation unit that calculates the total and each of the weights from the obtained detection results.
... |
| Citrate-based dialysate chemical formulations | 20090274774 | 20091105 |
| The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate... |
| Viral vaccine and method for preparation thereof | 20080317780 | 20081225 |
| The invention relates to a viral vaccine, especially a retroviral vaccine, and methods of forming such a vaccine. The vaccine is formed from a whole-killed virus suspension in a cell lysate or culture medium, wherein the virus is killed by exposure to a chloramine compound at a level adequate to inactivate zinc finger proteins. The chloramine compound may be taurine chloramine, adenosine chloramine, phenylalanine chloramine, and alanine chloramine. The vaccine may be used as a prophylactic or therapeutic vaccine and may be developed from a subject's own strains of virus so as to be considered an autologous vaccine.
... |
| High pressure processing of bioactive compositions | 20080317823 | 20081225 |
| The present invention relates to a method of pressure treating a bioactive composition comprising at least one bioactive component to prevent the growth of at least one unwanted microorganism while retaining a desired level activity of the at least one bioactive component. The bioactive component is selected from one or more proteins protein hydrolysates, one or more lipids or lipid hydrolysates, one or more carbohydrates, one or more probiotic factors, or mixtures thereof. The pressure treatment is at a predetermined pressure from about 350 to 1000 MPa.
... |
| Process flavours with low acrylamide | 20080317904 | 20081225 |
| The present invention describes novel yeast extract, autolysed yeast and protein hydrolysate with an amount of free asparagine not higher than 1 mg/g. This yeast extract, autolysed yeast or protein hydrolysate may be advantageously used in the production of a process flavour with an amount of acrylamide not higher than 800 ppb. This process flavour is particularly suitable to be used in flavouring of food or feed.
... |
| Absolute quantitation of protein contents based on exponentially modified protein abundance index by mass spectrometry | 20080319676 | 20081225 |
| The present inventor has established protein abundance index (PAI, π) to determine the protein contents in a protein mixture solution using nanoLC-MSMS data. Digested peptides were analyzed by nanoLC-MS/MS and the obtained results were applied to a Mascot protein identification algorism based on tandem mass spectra. PAI is defined as the number of observed peptides divided by the number of observable peptides per protein. PAI from different concentrations of serum albumin showed linear relationship to the logarithm of the protein concentration. This was also valid for 47 proteins in a mouse whole cell lysate analyzed by single run of nanoLC-MS/MS. On the other hand, Mascot protein scores as well as the number of identified peptides per protein were less correlated to the protein abundance. For absolute... |
| Two vessel reactor system and method for hydrolysis and digestion of wood chips with chemical enhanced wash method | 20080302492 | 20081211 |
| A reactor vessel system including: a first reactor vessel having a hydrolysate and liquid extraction screen, a first region above the extraction screen that is maintained at conditions promoting a hydrolysis reaction in the cellulosic material, a second region below the extraction screen in which the hydrolysis is substantially suppressed and a wash liquid inlet below the extraction screen providing wash liquid at a temperature below a hydrolysis temperature; a transport pipe having an inlet coupled to the first reactor vessel and an outlet coupled to a second reactor vessel, and the second reactor vessel includes a liquid discharge that extracts a portion of liquid from the second reactor vessel and directs the portion of liquid to the first reactor vessel or to the transport pipe.
... |
| Protein hydrolysate compositions having improved sensory characteristics and physical properties | 20080305212 | 20081211 |
| The present invention provides protein hydrolysate compositions, processes for making protein hydrolysate compositions, and food products comprising protein hydrolysate compositions. The protein hydrolysate compositions generally comprise polypeptide fragments having primarily either an arginine residue or a lysine residue at each carboxyl terminus.
... |
| Single vessel reactor system for hydrolysis and digestion of wood chips with chemical enhanced wash method | 20080295981 | 20081204 |
| A reaction vessel including: a material input receiving cellulosic material and a material discharge for the cellulosic material, wherein the cellulosic material flows through the reaction vessel from the material input to the material discharge; a hydrolysate and liquid extraction screen; a hydrolysis zone between the material input and the hydrolysate and liquid extraction screen; a wash zone between the hydrolysate and liquid extraction screen and a wash liquid extraction screen; a wash liquid inlet port for introducing a wash liquid into the wash zone, wherein at least a portion of the wash liquid entering the wash liquid inlet port flows through the wash zone and is extracted by the hydrolysate and liquid extraction screen; a cooking zone between the wash zone and the material discharge... |
| Solutions, dialysates, and related methods | 20080296226 | 20081204 |
| Solutions, dialysates, and methods for measuring solutes in blood and/or for treating blood. In one aspect of the invention, a method of performing dialysis includes placing a solution in communication with blood of a subject, where a concentration of at least one electrically conductive solute in the solution, prior to being placed in communication with the blood of the subject, is substantially equal to a concentration of the at least one electrically conductive solute in the blood of the subject.
... |
| Palatability enhancing compositions and foods for pets, and methods regarding the same | 20080299286 | 20081204 |
| Palatability enhancing compositions for pet foods, and pet foods with increased palatability, are provided. In some embodiments, the compositions and pet foods contain tea, such as green tea. In some embodiments, the compositions and pet foods contain brewer's yeast, liver hydrolysate, phosphate, and green tea. Shrimp meal and Tuna meal can also be utilized in these embodiments. In some embodiments, the compositions and pet foods comprise an ingredient having at least one of theanine; glutamine; tea; 1,5 octadien-3 one; 1,5-octadien-3-ol; and Camellia sinensis plant. In one example, green tea is used in a pet food palatability enhancing system at 0.1-25%, 1-15%, or 2-9% by weight of the system, and at 0.025-0.5% or 0.01 to 1.0% by weight of the pet food.
... |
| Miniprep system for simple and rapid plasmid dna extraction | 20080299621 | 20081204 |
| The invention relates to a modified microspin system for the isolation and purification of plasmid DNA. A disposable pre-filter column is used in combination with the traditional microspin column for increase speed and quality of plasmid DNA preparation. The disposable pre-filter column includes a pre-filter and a depth filter for optimal result. During plasmid DNA isolation, the lysate can be loaded directly to the assembly including the disposable pre-filter column and the microspin column. A quick spin causes the plasmid DNA to bind to the microspin column while the flocculents remain on top of the disposable pre-filter column, eliminates the need to first remove the flocculants containing cellular debris. This results in a much shortened process. Also provided are kits for isolation of plasmid DNA including... |
| Modified spin column for simple and rapid plasmid dna extraction | 20080300397 | 20081204 |
| The invention relates to a modified spin column for the isolation and purification of plasmid DNA. A pre-filtration disc is included in a traditional spin column. During plasmid DNA isolation, the lysate can be loaded directly to the modified spin column, eliminates the need to first remove the flocculants containing cellular debris. This results in a much shortened process. Variation of the invention includes a depth filter in between the pre-filtration disc and the main separation matrix. Also provided are kits for isolation of plasmid DNA including the modified spin columns.
... |
| Skin firming and lifting compositions and methods of use | 20080292651 | 20081127 |
| Disclosed is a composition comprising a combination of: Polygonum fagopyrum seed extract, Chlorella vulgaris extract, palmitoyl wheat protein hydrolysate, algae extract, and tripeptide. The composition may further comprise one or more of the following: Citrus unshiu peel extract, Sphacelaria scoparia extract, Bambusa vulgaris extract, Pisum sativum (pea) extract, Evodia rutaecarpa fruit extract, and dipalmitoylhydroxy proline. Such compositions are useful in methods for aiding in improving skin firmness, lifting the skin, preventing or decreasing skin sagging, and preventing or decreasing visible signs of aging resulting from internal and external causes such as environmental stresses.
... |
| Aromatization of a milk product using at least one bacterium producing a bacteriocin and belonging to the pediococcus genus | 20080292750 | 20081127 |
| The invention relates to a method of preparing a food ingredient conferring angiotensin-I-converting enzyme inhibiting properties to the food product comprising the ingredient, which method comprises providing a preparation of one or more protein hydrolysates having angiotensin-I-converting enzyme inhibiting properties, optionally together with one or more other constituents; adding one or more microorganism species to the preparation thus provided; and fermenting the preparation. The ingredient thus obtained has ACE-inhibiting properties and is no longer bitter tasting. The de-bittering can also take place directly in the food product for which the ingredient is intended.
... |
| Cosmetic compositions containing at least one conditioning agent and at least one ethylene polymer with polyethylene glycol grafts | 20080286218 | 20081120 |
| The invention concerns cosmetic compositions comprising: A) at least one conditioning agent selected among synthetic oils, mineral oils, vegetable oils, fluorinated and perfluorinated oils, natural or synthetic waxes, silicones, cationic polymers whereof the cationic filler density is less than 5 meq/g, cationic proteins, cationic protein hydrolysates, ceramide type compounds, cationic surfactants, fatty amines, fatty acids and their derivatives, as well as mixtures of those various compounds, and B) at least one ethylene copolymer comprising, in weight percentage based on the total weight of the polymer: a) 10-60 wt. % of one or more monomers of formula (I) as defined below; b) 40-90 wt. % of a substantially cationic monomer selected among (i) one or more cationic monomers of formula (IIa); (ii) one or more amphoteric monomers... |
| Hydrophobing minerals and filler materials | 20080286474 | 20081120 |
| A method of preparing a hydrophobic mineral and/or filler material, for example a gypsum material, comprises (i) preparing a hydrolyzate containing polysiloxanes by hydrolyzing a hydrolysable silane or hydrolysable silane mixture in the presence of an acid hydrolysis catalyst; and (ii) combining the polysiloxane hydrolyzate with the mineral and/or filler, and optionally water and/or a catalyst for condensation of the hydrolysate.
... |
| Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides | 20080286838 | 20081120 |
| A shortened process for producing a solution containing substantially purified capsular polysaccharides from a cellular Streptococcus pneumoniae lysate broth is described. Ultrafiltering and diafiltering a clarified S. pneumoniae lysate followed by pH adjustment to less than 4.5, preferably about 3.5, precipitated at least 98% of the protein in the solution without seriously affecting polysaccharide yield. Furthermore, following ultrafiltration and diafiltration and acidification to a pH of less than 4.5, filtration using activated carbon precipitated at least 90% of remaining protein without seriously affecting polysaccharide yield. Exemplary, non-limiting S. pneumoniae serotypes that can be purified using the shortened process of the invention are 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. In one embodiment, the Streptococcus pneumoniae cells are lysed using deoxycholate... |
| Zirconium oxide-tin oxide composite sol, coating composition and optical member | 20080276835 | 20081113 |
| The present invention relates to a sol comprising zirconium oxide-tin oxide composite colloidal particles (A), wherein a molar ratio of oxide in the zirconium oxide-tin oxide composite colloidal particles (A) is 0.02-0.4 as SnO2/ZrO2, and the zirconium oxide-tin oxide composite colloidal particles (A) have a structure in which zirconium oxide colloidal particles and tin oxide colloidal particles are bonded together, and a primary particle diameter of 2-100 nm; and also relays to a coating composition comprising a silicon-containing substance (S) of an organic silicon compound or a hydrolysate thereof, and a sol comprising zirconium oxide-tin oxide composite colloidal particles (A), and an optical member having a cured coating formed from the coating composition.
... |
| Methods for enhancing palatability of compositions for animal consumption | 20080280274 | 20081113 |
| Poultry liver hydrolysate is added to animal food compositions in amounts sufficient to enhance palatability, preferably in amounts of from about 0.01% to about 6% by weight of the composition. The compositions containing poultry liver hydrolysate are ingested more frequently and at a higher rate by animals, particularly finicky animals or older animals that tend not to eat enough food to maintain their health.
... |
| Pigmented and internally impregnated fibrous cellulose sausage casing | 20080274237 | 20081106 |
| The invention relates to a double-viscosed fibrous cellulose sausage casing having a pigmented outer cellulose hydrate layer and an impregnated internal cellulose hydrate layer. The impregnation of the internal cellulose hydrate layer includes a collagen hydrolysate and the outer cellulose hydrate layer includes at least one white pigment, preferably having titanium dioxide pigments. The invention further relates to a method for producing the fibrous cellulose sausage casing and also to its use as artificial sausage casing.
... |
| Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions | 20080275140 | 20081106 |
| The present invention provides a process to make a gelatine hydrolysate, a gelatine hydrolysate, and gelatine compositions including gelatine hydrolysates. More specifically, the invention provides gelatine compositions having a reduced tendency to cross-link and improved dissolution properties.
... |
| Acerola fruit-derived pectin and its application | 20080267894 | 20081030 |
| The present invention relates to a pectin derived from an acerola fruit or a hydrolysate thereof, comprising a complex formed of Aceronidin, which is a novel polyphenol compound. The pectin of the present invention can be used as an active ingredient of an antioxidant or a skin-whitening agent.
... |
| Gelation of anionic polysaccarides using protein hydrolysates | 20080268127 | 20081030 |
| According to the present invention hydrocolloid compositions are provided comprising anionic polysaccharides as well as an amount of peptide material. These hydrocolloid compositions can suitably be used to gel and/or viscosify aqueous systems. Interactions between said anionic polysaccharides and said peptides in aqueous systems result in cross-linked polymer networks. According to the present invention the peptides are typically obtained by hydrolysing protein compositions and optionally subsequently isolating or purifying a cationic fraction therefrom. The use of the present gelled and/or viscosified aqueous systems in e.g. foodstuffs, beverages, encapsulates and pharmaceutical and/or cosmetic compositions are disclosed herein.
... |
| Rna interference mediating small rna molecules | 20080269147 | 20081030 |
| Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3′ ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
... |
| Synergistic prebiotic compositions | 20080261916 | 20081023 |
| The invention relates to synergistic compositions comprising prebiotic components selected from fructose polymers GFn and Fm, either containing a glucose (G) end-group, or without a glucose end-group, and one or more component of a group of prebiotics consisting of modified or unmodified starch and partial hydrolysates thereof, partially hydrolysed inulin, natural oligofractoses, fructo-oligosaccharides (FOS), lactulose, galactomannan and suitable partial hydrolysates thereof, indigestible polydextrose, acemannan, various gums, indigestible dextrin and partial hydrolysates thereof, trans-galacto-oligosaccharides (GOS), xylo-oligosaccharides (XOS), beta-glucan and partial hydrolysates thereof, together if desired with phytosterol/phytostanol components and their suitable esters, and if desired other plant extracts, mineral components, vitamins and additives.
... |
| Hemodialyzer | 20080251433 | 20081016 |
| Provided is a hemodialyzer in which deterioration in membrane performance of a hollow fiber with time can be grasped accurately during dialysis and the performance can be recovered quickly and positively. The hemodialyzer, constituted by connecting an artery side blood circuit (2) having a blood pump (7) to the artery side of a dialyzer (1), connecting a vein side blood circuit (3) to the vein side of the dialyzer (1), and connecting a dialysate supply line (4) and a dialysate discharge line (5), respectively, to the side face of the dialyzer (1), is provided with a detector (15) for determining the pressure in the blood circuit, and a detector (16) for determining the pressure in the dialysate line, in which transmembrane pressure is calculated based on... |
| Whey protein hydrolysate | 20080254505 | 20081016 |
| The present invention relates to a method of producing a whey protein hydrolysate using a microbial endopeptidase which specifically cleaves on the carboxy terminal side of arginine or lysine. The invention also relates to use of such whey protein hydrolysate in sports drinks or in clinical nutrition.
... |
| Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate | 20080254514 | 20081016 |
| The invention concerns a method for large-scale production of a polypeptide in eukaryote cells contained in a serum-free culture liquid, said method comprising (i) a propagation phase for said cells, where the cells are propagated in a first cell culture liquid, and (ii) a production phase for said cells, where the cells are present in a second cell culture medium liquid, wherein each of the cell culture liquids comprise a plant protein hydrolysate, and wherein the ratio between the concentration of the plant protein hydrolysate (C1) in the first cell culture liquid and the concentration of the plant protein hydrolysate (C2) in the second cell culture liquid is at least 1.5:1 (C1:C2).
... |
| Animal medicament and method of manufacture | 20080248014 | 20081009 |
| A medicament for administration to a non-human animal, wherein the medicament includes at Least partially hydrolysed protein and one or more pharmacologically active substances. In a preferred embodiment, the protein is derived from meat which is hydrolysed using a fruit-derived proteolytic enzyme such as actinidin from kiwifruit which enhances the palatability of the resulting hydrolysate. A method of manufacturing the medicament, and a method of medicating a non-human animal by administering to the animal a medicament are also disclosed.
... |
| Mixture for oocytes maturation in art laboratory | 20080248573 | 20081009 |
| Women over 40 years and those who had ovarian problems suffer from low pregnancy rate after Assisted Reproduction Technology (ART) procedure due to immature oocytes. According to the invention a mixture is added to these oocytes. This mixture consists of two substances: Substance 1 which has the ability of stimulating cell proliferation in vitro by increasing the oxygen uptake of the cell and substance 2 which is any of the most used media in ART laboratories. Substance 1 is protein-free haemodialysate of calves blood. The created mixture in more than one concentration succeeded in complete oocytes maturation from immature to complete matured ones, able to be injected and fertilized by sperm. A second aspect of the invention is the use of the mixture to increase motility... |
| Polysulfone hemodialyzer | 20080237127 | 20081002 |
| An object of the present invention is to provide a polysulfone hemodialyzer with large membrane area that exhibits an unprecedented high dialytic performance over a wide molecular weight range from urea to β2-microglobulin. There is provided a polysulfone hemodialyzer having a membrane area of >2.4 but ≦3.2 m2 and a dialysate rectifying portion with specified broadening at end portion of bundle, the polysulfone hemodialyzer achieves the above object.
... |
| Product release system to atomize compositions containing hair-conditioning ingredients | 20070297992 | 20071227 |
| A product release system to atomize cosmetic hair compositions is described, which has (a) pressure-resistant packaging, (b) a capillary-containing spray head, and (c) a propellant-containing cosmetic composition, and wherein the composition contains at least one hair-conditioning ingredient, which is selected from cationic surfactants, amino surfactants, silicone compounds, fatty alcohols, oils, plant extracts, protein hydrolysates, amino acids, panthenol, panthenyl ethyl ether, sorbitol, betaine, and creatine. The atomization is done using the capillary. The capillary preferably has a diameter of 0.1 to 1 mm and a length of 5 to 100 mm. The spray rate is preferably 0.01 to 5 g/s. The composition can particularly be a gel, wax, or emulsion.
... |
| Casein hydrolyzate, process for producing the same and use thereof | 20070299014 | 20071227 |
| The present invention relates to a casein hydrolysate containing free amino acids and in vivo indigestible peptides having minimally suppressed in vivo enzymatic digestibility, and expected to express functions, such as hypotensive effect, in living organism, and to a method for preparing such a hydrolysate, and use thereof. The casein hydrolysate of the present invention contains free amino acids and peptides, such as in vivo indigestible peptides including Xaa-Pro and Xaa-Pro-Pro, obtained by hydrolyzing animal milk casein to have an average chain length of not longer than 2.1 in terms of the number of amino acid residues, and has ACE inhibitory activity or hypotensive effect.
... |
| Hydrolysate of avian cartilage, process of preparation and uses thereof | 20070293427 | 20071220 |
| This invention relates to a hydrolysate of avian cartilage comprising 45% to 70% by weight of hydrolysed type II collagen, 9% to 15% by weight of chondroitin sulphate, 0.5% to 2% in weight of hyaluronic acid; with a composition of amino acids in which valine represents 2.7% to 3.3%, isoleucine represents 2.0 to 2.4, phenylalanine represents 2.2% to 2.6%, lysine represents 3.8% to 4.2%, tryptophane represents 0.4% to 0,6%, hydroxyproline represents 5.5% to 8.7%, hydroxylysine represents 0.7% to 1.8%, and in which the molar ratio between hydroxyproline and hydroxylysine is between 5.0 and 8.0; and having an average molecular weight of the peptidic fraction between 500 and 1000 Daltons. The invention also relates to a process for preparing said hydrolysate, and its use as a food... |
| Polarizing plate protective film, reflection preventive polarizing plate and optical product | 20070287009 | 20071213 |
| A polarizing plate protective film including a base film and a low-refractive-index layer formed on the base film, the low-refractive-index layer including a metal oxide complex and inorganic microparticles and having a refractive index of 1.25 to 1.37, the metal oxide complex being formed from a compound shown by the following formula (1): MXn (wherein M represents a metal atom or a semimetal atom, X represents an alkoxy group or the like, and n represents the valence of M) or a partial hydrolysate or a complete hydrolysate of the compound shown by the formula (1), and having an —(O-M)m-O— bond (wherein M is the same as defined above, and m represents a positive integer) in the molecule; a reflection preventive polarizing plate using the polarizing plate... |
| Compositions and methods for prevention or treatment of thrombocytopenia and methods for manufacturing said compositions | 20070287661 | 20071213 |
| This invention teaches a composition of peptides, amino acids, and microelements derived from keratin-containing animal material for treating thrombocytopenia and a method for manufacturing thereof, comprising hydrolyzing keratin-containing animal materials, and particularly animal nails, to obtain a hydrolysate; filtering and concentrating the hydrolysate; admixing alcohol; and purifying the resultant solution. In addition, the invention teaches a method for treating (curing and/or preventing) thrombocytopenia by administering parenterally to a patient a pharmaceutical composition comprising an excipient and a composition of peptides, amino acids, and microelements derived from keratin-containing animal material.
... |
| Room temperature-curable organopolysiloxane composition | 20070282047 | 20071206 |
| The present invention is capable of forming a rubber elastomer which exhibits excellent adhesion to resins whose adhesion has been difficult, for example, polyimide resin.
... |
| Room temperature-curable organopolysiloxane composition | 20070282061 | 20071206 |
| (E) 0.01 to 10 parts by weight of a curing catalyst. The mass ratio of the component (B) to the component (C) is less than 1.
... |
| Use of a cruciferous protein hydrolysate as a depigmentation agent or for a cosmetic and/or pharmaceutical composition | 20070274937 | 20071129 |
| A composition and method for whitening and/or depigmenting skin with a protein hydrolysate from plants belonging to the crucifer family.
... |
| Process for treating the surface of fresh meat | 20070275141 | 20071129 |
| The present invention creates a process for treating the surface of fresh meat, in which the meat is treated with a hydrocolloid based on collagen, in particular gelatine, animal glues, collagen, caseins, whey proteins and/or their hydrolysates as well as their mixtures with one another. In particular a weight loss of the meat during storage due to escaping drip is thereby prevented. In the process according to the invention the meat is preferably treated with 0.2 to 1.5 wt % of hydrocolloid, referred to the weight of the meat. It is possible with said process to treat all kinds of meat suitable for human consumption, in particular mammal meat, poultry and fish.
... |
| Room temperature-curable organopolysiloxane composition | 20070276085 | 20071129 |
| (d) a calcium carbonate.
... |
| Automated dialysis system driven by gravity and vacuum | 20070276328 | 20071129 |
| A peritoneal dialysis machine includes: (i) a supply bag; (ii) an apparatus configured to support the supply bag, the supply bag located above the peritoneal cavity of a patient; (iii) a vacuum source; (iv) a patient line configured to be connected to the patient; (v) a drain line configured to be connected to a drain; and (vi) a logic implementor configured to enable (a) fresh dialysate to be gravity fed from the supply bag through the patient line to the peritoneal cavity during a fill cycle and (b) the vacuum source to cause spent dialysate to be pulled from the peritoneal cavity through the drain line to the drain during a drain cycle.
... |
| Automatic reinfusing system | 20070262013 | 20071115 |
| An automatic reinfusing system which involves no contamination or medical errors or any other operational problems and allows easy and simple operation, without imposing any burden on the medical worker. The automatic reinfusing system includes a hemodialysis circuit, wherein a solution replenishing line has a replenishing solution supply source and an opening and closing arrangement for opening and closing the solution replenishing line, a dialysate supply line and a dialysate discharge line for perfusing to the dialyzer, with a solution feeding arrangement being respectively provided for the dialysate supply line and the dialysate discharge line. At least one filtering and reverse-filtering third solution feeding arrangement capable of normal and reverse rotation and allowing flow rate control serves to perform filtering and reverse filtering on one of... |
| Method for rapid identification of molecules with functional activity towards biomolecular targets | 20070264661 | 20071115 |
| The present invention provides mass spectrometry-based methods for high throughput identification of molecules with functional activities such as nuclease, protease, reductase, kinase, phosphatase, or transferase activities towards biomolecular targets. These methods are useful for screening biological samples such as extracts, broths, lysates and natural product mixtures and provide valuable insights into biomolecular interactions of various biological ligands with biomolecular targets.
... |
| Method for preparing solid polyorganosiloxane | 20070255034 | 20071101 |
| provided that the step [2] may be performed before, during, or after the step [1].
... |
| Determination of proteins and/or other molecules using mass spectroscopy | 20070249060 | 20071025 |
| This invention generally relates to the determination of species such as proteins and/or small molecules on self-assembled monolayers using mass spectrometry. In some cases, the proteins and/or small molecules may be arranged on a substrate in an array, for example, in a microarray. In one set of embodiments, the invention relates to methods for determining proteins and/or small molecules bound to self-assembled monolayers using mass spectroscopy techniques such as MALDI and MALDI TOF techniques. This combination allows, for example, the systematic identification of unknown proteins from cell lysates. Identification of novel interactions can be achieved, in some cases, in instances where the binding partner to a particular target species is unknown. In another set of embodiments, the invention relates to methods of attaching a species to... |
| Film for membrane structure | 20070243373 | 20071018 |
| A film for a membrane structure, which comprises a film substrate containing a fluororesin, a photocatalyst layer and an interlayer interposed between the film substrate and the photocatalyst layer, wherein the fluororesin is at least one member selected from the group consisting of an ethylene/tetrafluoroethylene copolymer, a tetrafluoroethylene/hexafluoropropylene copolymer, a tetrafluoroethylene/perfluoro(alkyl vinyl ether) copolymer, a polyvinyl fluoride and a polyvinylidene fluoride; the interlayer contains an organic-inorganic hybrid polymer obtained by hydrolyzing/co-condensing at least one member selected from the group consisting of an organosilane, a hydrolysate of an organosilane and a condensate of an organosilane, and a silyl group-containing organic polymer; and the mass remaining ratio of the organic-inorganic hybrid polymer is from 50 to 80% at 500° C. measured by thermogravimetric analysis.
... |
| Anti-smudge agent, smudge proof coating composition, smudge proof film, and article coated with smudge proof film | 20070243394 | 20071018 |
| When the coating composition having the anti-smudge agent of the present invention blended therein is used for the coating, the surface will provided with the smudge proof property simultaneously with the functions realized by the base resin of the coating composition by one coating, and provision of two separate coatings is no longer necessary. This is economically by far advantageous.
... |
| Method for coating metal surfaces | 20070238257 | 20071011 |
| A composition for producing a protective coat against scaling on metallic surfaces. The composition includes, as binders, hydrolysates/condensates of at least one silane or a silicone resin binder and also, further, at least one metallic filler.
... |
| Methods related to wound healing | 20070231297 | 20071004 |
| The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.
... |
| Cancer vaccine | 20070231351 | 20071004 |
| The present invention relates to a method for producing a composition for use as a vaccine for treatment or prevention of cancer. The method includes the steps of isolating dendritic cells from a blood, bone marrow or other tissue sample of a patient suffering from cancer or from an unrelated donor, culturing the dendritic cells under conditions and pulsing the dendritic cells with tumour cell lysate or an antigen released by the type of tumour cell and a tocotrienol.
... |
| Long-duration encapsulated flavors and chewing gum using same | 20070231424 | 20071004 |
| A chewing gum composition comprises about 5% to about 95% gum base, about 5% to about 96% bulking and sweetening agents, and about 0.1% to about 15% flavor, wherein at least part of the flavor is a long-duration flavor material comprising a vinyl polymer encapsulated matrix. The matrix itself includes about 30% to about 60% acacia gum, about 30% to about 60% corn syrup solids having a DE of between about 24 and about 44 or equivalent hydrogenated starch hydrolysates, and about 2% to about 20% hydrocolloid material, with the acacia gum and corn syrup solids or hydrogenated starch hydrolysates together comprising at least 80% of the matrix. The vinyl polymer comprises between about 30% and about 80% of the long-duration flavor material.
... |
| Optical recording medium and method for producing same | 20070231527 | 20071004 |
| It is to obtain an optical recording medium having sufficient stainproof properties and adhesion in a simple and industrially advantageous process. On an optical recording medium comprising a substrate, and a recording and retrieving layer formed on the substrate, a light transmitting layer to be formed on the recording and retrieving layer formed by curing a composition containing silica particles and an oligomer having a urethane bond and capable of being cured by irradiation with radiation, and a stainproof layer to be formed on the light transmitting layer, containing an alkoxysilane compound containing a fluorine atom and/or a hydrolysate of the alkoxysilane compound, are provided.
... |
| Magnetic recording medium | 20070231610 | 20071004 |
| A magnetic recording medium including a support having thereon a magnetic layer and a non-magnetic layer in this order, the magnetic layer being formed by applying and drying a magnetic nanoparticle dispersion liquid in which magnetic nanoparticles having a number average particle diameter of 20 nm or less are dispersed, applying the non-magnetic layer onto the magnetic layer, fixing the magnetic nanoparticles, and carrying out annealing for ferromagnetization, and the non-magnetic layer containing a gelatinous composition formed by gelating at least one selected from hydrolysates of the silane compound represented by (R10)m—Si(X)4-m and partial condensates thereof, wherein R10 represents a substituted or unsubstituted alkyl group, or a substituted or unsubstituted aryl group; X represents a hydroxy group or hydrolyzable group; and m represents an integer from... |
| Compressed gum | 20070224310 | 20070927 |
| The present invention generally relates to a granulated chewing gum composition which may be compressed, and to a process for the preparation thereof. In particular, the present invention relates to such a granulated chewing gum composition which comprises a solid hydrogenated starch hydrolysate, as well as to a process for the preparation thereof. Additionally, or alternatively, the present invention relates to a process for preparing a granulated chewing gum composition, wherein a chewing gum base is used therein which may be comminuted at an elevated temperature, as well as a composition comprising such a base. The granular chewing gum composition may be compressed into a tablet, and optionally coated.
... |
| Process for the preparation of compressed gum | 20070224311 | 20070927 |
| The present invention generally relates to a granulated chewing gum composition which may be compressed, and to a process for the preparation thereof. In particular, the present invention relates to such a granulated chewing gum composition which comprises a solid hydrogenated starch hydrolysate, as well as to a process for the preparation thereof. Additionally, or alternatively, the present invention relates to a process for preparing a granulated chewing gum composition, wherein a chewing gum base is used therein which may be comminuted at an elevated temperature, as well as a composition comprising such a base. The granular chewing gum composition may be compressed into a tablet, and optionally coated.
... |
| Extracting enzymes from raw materials | 20070224315 | 20070927 |
| The present technology relates to a method for extracting enzymes from an enzyme-containing raw material, an enzyme composition obtainable by the method, and to the use of the enzyme composition for the hydrolysis of proteins or as a food supplement. Further, the present technology relates to a method for producing a protein hydrolysate from a protein-containing raw material.
... |
| Medical and health-care uses of pufferfish type i collagen extract and processes for producing said extract | 20070219128 | 20070920 |
| The present invention relates to the use of pufferfish type I collagen extract as effective ingredient in the manufacture of medicaments and health-care foods for prevention and treatment of the following diseases, wherein the main chemical components and active components of the pufferfish type I collagen extract are natural pufferfish type I collagen or denatured pufferfish type I collagen extract and partial hydrolysates thereof. The present invention further relates to processes for the production of said pufferfish type I collagen extract, immunological assay methods of said extract, and uses of said extract as effective ingredient in treatment and health-care.
... |
| Method for purifying plasmid dna | 20070213289 | 20070913 |
| This invention provides a process for the continuous alkaline lysis of a bacterial suspension in order to harvest pDNA. It further provides for optional additional purification steps, including lysate filtration, anion exchange chromatography, triplex affinity chromatogragphy, and hydrophobic interaction chromatography. These optional purification steps can be combined with the continuous lysis in order to produce a highly purified pDNA product substantially free of gDNA, RNA, protein, endotoxin, and other contaminants.
... |
| Virus purification methods | 20070207461 | 20070906 |
| The invention provides a method for the purification of a virus from a host cell, the method comprising the steps of: a) culturing host cells, b) infecting the host cells with a virus, c) treating the cell culture with nuclease, d) lysing the host cells to provide a lysate comprising the virus. The virus is preferably a recombinant adenovirus. The invention further provides a method for the purification of a recombinant virus expressing a heterologous protein that is capable of binding nucleic acid, comprising the steps of: a) culturing host cells, b) infecting the host cells with the recombinant virus, c) lysing the host cells to provide a lysate comprising the recombinant virus, d) subjecting the recombinant virus to anion exchange chromatography and size exclusion chromatography,... |
| Buffers for detection of mrna separated in a microfluidic device | 20070207483 | 20070906 |
| The present invention provides methods and kits using low conductivity buffers for the detection of mRNA from a cell lysate separated in a microfluidic device. The buffers do not affect the integrity of the cell nucleus, thereby allowing for generation of a cell lysate that can be directly used as a template in reverse transcriptase (RT)-polymerase chain reaction (PCR) amplification reactions without contaminating genomic DNA.
... |
| Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof | 20060292129 | 20061228 |
| The present invention relates to a cell line selected from the group consisting of (a) a cell line denominated NM-F9 having the DSMZ accession number DSM ACC2606; (b) a cell line denominated NM-D4 having the DSMZ accession number DSM ACC2605; and subclones of (a) or (b). Additionally, the present invention provides a lysate of the cell lines or a molecule or mixture of molecules obtained from these cell lines as well as dendritic cells loaded with said lysate, co-cultivated or fused with cells from the cell lines, or a molecule or mixture of molecules obtained from these cell lines of the present invention. Moreover compositions, preferably pharmaceutical or vaccine compositions are provided which comprise the cell lines, lysate, molecules, mixture of molecules or dendritic cells of... |
| Method for improving solubility and folding efficiency of target proteins using rna as molecular chaperone | 20060292667 | 20061228 |
| Disclosed is a method for improving folding efficiency and solubility of a target protein linked to a RNA-binding protein by using RNA molecule as a molecular chaperone, wherein the RNA molecule interacts with the RNA-binding protein. More particularly, the present invention discloses method for improving folding efficiency and solubility of a target protein by transformation of a host cell with a expression vector comprising a polynucleotide encoding the target protein linked to an RNA-binding protein; culturing the transformed host cell in an appropriate culture medium under the condition that an RNA molecule either resident inside the host cell or provided by cotransformation of the host cell with polynucleotide encoding the RNA molecule interacts with the RNA-binding protein; and purifying the soluble protein from host cell lysate.... |
| Biomass hydrolysate and uses and production thereof | 20060286205 | 20061221 |
| The present invention includes a palatable, stable composition comprising a biomass hydrolysate emulsion for incorporation, into, or used as, nutritional products, cosmetic products or pharmaceutical products. Preferred sources for biomass are microbial sources, plant sources and animal sources. The present invention also provides methods for making such compositions, specifically, a method for producing a product comprising a nutrient, particularly a long chain polyunsaturated fatty acid, comprising hydrolyzing a biomass comprising the nutrient and emulsifying the hydrolyzed biomass. Such compositions and methods are useful, for example, for increasing intake of nutrients such as omega-3 long chain polyunsaturated fatty acids having 18 or more carbons.
... |
| Methods for producing protein partial hydrolysates and infant formulas containing the same | 20060286208 | 20061221 |
| The present invention relates to a process for preparing a protein partial hydrolysate. The process involves intermixing a solution of whey protein, casein and water; adjusting the temperature and pH of the solution, adding Protease N to the solution, and allowing the solution to hydrolyze for a period of time so as to obtain a degree of hydrolysis between about 4% and 10%. The hydrolysis is ended by subjecting the solution to enzyme deactivation.
... |
| Normalization of samples for amplification reactions | 20060286558 | 20061221 |
| The present invention provides oligonucleotide primers, compositions, methods, and kits for determining the number of cells from which a cell lysate originated. The invention relies on detection and amplification of unique genomic sequences within the genome of an organism of interest to determine the amount of genomic nucleic acid in a sample. The invention can be used to normalize samples from particular cells, cell types, or organism, and provide an accurate basis for comparison of expression of genes across the samples.
... |
| Soluble dietary fibre from oat and barley grains, method for producing a fraction rich in b-glucan and use of the fraction in foods, pharmaceuticals and cosmetics | 20060280838 | 20061214 |
| The present invention relates to a process for the extraction of soluble dietary fibre from oat and barley grains using enzymatic hydrolysis treatment, wherein the grain is milled and any endosperm depleted fractions thereof being rich in β-glucans are recombined, without further heat treatment, dispersed in water and then subjected to sequential enzymatic treatment with starch degrading enzymes, followed by an optional step of enzyme inactivation by wet heat treatment, and a subsequent step wherein the hydrolysate mixture is spontaneously or centrifugally separated into at least 3 distinct fractions: a first fraction, which comprises the soluble dietary fibre complex, containing more than 20% B-glucan on a dry matter basis, a second aqueous fraction, and a third fraction comprising most of the protein and oil together with... |
| Silicone composition for water-repellent coating | 20060281889 | 20061214 |
| where R is a C1 to C10 monovalent hydrocarbon group, Q is an oxygen atom or a C2 to C10 alkylene group, and n is an integer from 10 to 1000; (B) an alkoxysilane partial hydrolysate/condensate, where the alkoxysilane is described by general formula: R1xSi(OR2)4-x, where R1 is a C1 to C6 monovalent hydrocarbon group, R2 is a C1 to C6 alkyl group, and x is an integer from 0 to 3; (C) an organotitanium-based catalyst; (D) an aliphatic hydrocarbon solvent or ester-based solvent; and (E) an alcohol-based solvent.
... |
| Collagen hydrolysate | 20060275345 | 20061207 |
| The use of collagen hydrolysate as dietary supplement to baby food, particularly to improve the general state of health in infants and bring about a reduction in restlessness, vomiting after food intake and flatulence, is disclosed.
... |
| Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions | 20060269987 | 20061130 |
| The present invention provides a process to make a gelatine hydrolysate, a gelatine hydrolysate and gelatine compositions comprising gelatine hydrolysates. More specifically, the invention provides gelatine compositions having improved cross-linking and dissolution properties.
... |
| Immunodiagnostic assays using reducing agents | 20060263854 | 20061123 |
| The present invention relates to a solid phase immunoassay comprising on said solid phase an antigen in the presence of a reducing agent. The present invention also relates to a method for purifying a cysteine containing recombinantly expressed protein comprising at least 2, preferably 3 or 4 and even more preferably all of the following steps: (a) sulphonation of a lysate from recombinant host cells or lysis of recombinant host cells in the presence of guanidinium chloride followed by a subsequent sulphonation of the cell lysate, (b) treatment with a zwitterionic detergent, preferably after removal of the cell debris, (c) purification of the sulphonated version of the recombinant protein or purification of the sulphonated version of the recombinant protein with subsequent removal of the zwitterionic detergent,... |
| Composition for photocatalyst coating and coating film | 20060264525 | 20061123 |
| Photocatalytic coating compositions contain a photocatalytic material such as obtained by doping nitrogen atoms to an interstitial site of metal oxide crystals, a titanium compound having a specific structure, an organosilane hydrolysate having a specific structure, and an organosiloxane oligomer having a specific structure. The photocatalytic coating compositions can give coating films that exhibit adequate photocatalytic action even in an environment with less spectral components having wavelengths of 400 nm or below and more visible light, for example in an indoor environment and in vehicle interiors having UV protection glass, and that have high transparency. Further, the photocatalytic coating compositions have good storage stability of dispersions.
... |
| Compositions for potentiating glutatthione | 20060257351 | 20061116 |
| A composition for potentiating glutathione, which contains at least one member selected from the group consisting of 2-(3,4-dihydroxyphenyl)ethanol or a glycoside thereof, a plant containing 2-(3,4-dihydroxyphenyl)ethanol or a glycoside thereof, an extract of said plant, a hydrolysate of said plant, and a hydrolysate of the extract of said plant (excluding Olea europaea and an extract thereof), and which further contains at least one member selected from among an S-containing compound that is a supply source of cysteine, a protein that contains cysteine and/or cystine, a yeast that contains cysteine and/or cystine, and a vitamin.
... |
| Use of tryptophan rich peptides | 20060257497 | 20061116 |
| The novel use of peptides derived from whey protein hydrolysate as active ingredient in a medicament or as food ingredient for elevating the cholescystokinin level in the blood, and for preventing or treatment of overweight and/or obesity, in an animal, including human, in need thereof.
... |
| Hair treatment agents with surfactant mixtures | 20060251602 | 20061109 |
| The invention relates to a composition useful as a cosmetic hair treatment agent based on a) a surfactant mixture containing: A) at least one anionic surfactant; B) at least one amphoteric surfactant, and; C) at least one additional surfactant selected from the group consisting of acyl glutamates, amino oxides and of alkyl polyglucosides. The surfactant mixture also contains: b) at least one additional hair care substance selected from the group consisting of fatty alcohols, cationic surfactants, cationic polymers, cationically derivatized protein hydrolysates, water-insoluble volatile silicones and/or of water-soluble volatilized silicones and vitamins and/or provitamins and/or physiologically compatible derivatives thereof. This agent can be excellently formulated as a 2-in-1 shampoo that, while simultaneously cleaning and caring for, also positively influences the volume and body of the hair.
... |
| Pharmaceutical composition containing disrupted cell suspension of monilia albicans and euglobulin and method of treating animals infected with canine distemper virus or animals having neurological disorders by using the same | 20060252092 | 20061109 |
| Disclosed is a pharmaceutical composition which comprises a disrupted cell suspension of Monilia albicans and euglobulin as effective ingredients, wherein the disrupted cell suspension of the Monilia albicans is prepared by culturing the Monilia albicans in a liquid culture medium, centrifuging the resulting culture fluid, recovering the supernatant and disrupting the collected cells, and mixing the supernatant and the cell lysate after inactivation, wherein the culture fluid contains the Monilia albicans of about 1.2×109 cfu/ml. Also, the present invention discloses a method of treating animals infected with canine distemper virus or animals with neurological disorders.
... |
| Separating column, especially for a miniaturised gas chromatograph | 20060243140 | 20061102 |
| The invention relates to a separating column, especially for miniaturised gas chromatograph. In addition to a micro-chromatograph provided with one or more inventive separating column. The inventive separating column prevents the known racetrack effect and can therefore be produced in a simple and economical manner. The separating column (1) comprises a channel (2) for a flow of fluid having analysate molecules. The flow of fluid comprises counter flowing curves (3, 4) with turning points (7, 8), the average diameter of the channel (2) is greater than the length of the path traversed by an analysate molecule when diffused between two turning points (7, 7a; 8, 8a).
... |
| Method for extraction and identification of nucleic acids | 20060240409 | 20061026 |
| The invention provides a method for extracting nucleic acids from a sample. The sample contains cells, viruses, or both cells and viruses. The method include adding a lysing solution containing a detergent to the sample to lyse the cells or viruses to form a lysate, adding alcohol to the lysate to aggregate or precipitate the nucleic acids, and purifying the nucleic acids from the lysate-alcohol mixture by filtering the mixture through a glass-fiber filter.
... |
| Cell concentration and lysate clearance using paramagnetic particles | 20060240448 | 20061026 |
| Methods are disclosed for using paramagnetic particles to concentrate or harvest cells. Methods are also disclosed for clearing a solution of disrupted biological material, such as a lysate of cells or a homogenate of mammalian tissue. Methods are also disclosed for using paramagnetic particles to isolate target nucleic acids, such as RNA or DNA, from a solution cleared of disrupted biological material using the same type or a different type of paramagnetic particle. Kits are also disclosed for use with the various methods of the present invention. Nucleic acids isolated according to the present methods and using the present kits are suitable for immediate use in downstream processing, without further purification.
... |
| Method for installing and servicing a wearable continuous renal replacement therapy device | 20060241543 | 20061026 |
| A continuous renal replacement therapy (CRRT) device that is completely worn on the body of a patient. A protocol is provided for installing the completely wearable CRRT device on a patient and changing or exchanging various CRRT device parts and fluids at predetermined intervals. A dialyzer or hemofilter is changed in a sterile environment while the dialysate and dialysate filters can be changed in a non-sterile environment by the patient.
... |
| Method of producing pure halide salts of alkaline and/or alkaline earth metal resulting from hydrolytic treatment of halogenous organic waste material | 20060231493 | 20061019 |
| Pure halogen salts of alkaline and/or alkaline earth metals or a mixture thereof are prepared by (I) hydrolytically heating a suspension of 1 part by weight of a halogenic, organic waste material in a comminuted state in 1-10 parts by weight of an aqueous medium in the presence of a base to a temperature ranging from 200-300° C. at a pressure sufficient to maintain the water in a liquid state for a period of time sufficient to convert substantially all the organically bound halogen present to inorganic halides, and (II) separating the hydrolysate obtained in step (I) into a solid hydrolysate fraction and a liquid hydrolysate fraction, (III) neutralizing the liquid hydrolysate with hydrohalogenic acid, (IV) adding a flocculent to the neutralized hydrolysate; (V) separating the... |
| Composition for luring and controlling arthropods comprising synthetic silicic acid and protein autolysate | 20060233848 | 20061019 |
| The invention relates to a composition comprising protein autolysates derived from yeasts and synthetic silicic acids, and also, optionally, active compounds directed against animal pests, for luring and controlling animal pests, which composition can be used in agriculture, in horticulture, in forestry, in animal husbandry, in animal breeding, in the protection of stored products, in the protection of materials, in the hygiene sector and in the domestic field.
... |
| Pyroglutamyl peptidase and its gene | 20060234320 | 20061019 |
| The present invention provides DNA encoding novel pyroglutamyl peptidase derived from Aspergillus oryzae, pyroglutamyl peptidase which is produced by using the DNA, and a method for producing a protein lysate with a good flavor at a high hydrolysis rate.
... |
| Method of production of rna polymerase protein | 20060234348 | 20061019 |
| A method of forming a stable RNA polymerase enzyme by expressing protein 2a in cells, pelleting the cells expressing protein 2a, macerating the cells expressing protein 2a to obtain a cell lysate, and filtering the cell lysate through an affinity resin. A stable RNA polymerase enzyme for copying RNA in vitro for use is disclosed.
... |
| Methods of purification of cytochrome p450 proteins | 20060234365 | 20061019 |
| The invention provides a method for the purification of cytochrome P450 molecules, the method comprising expressing in a host cell culture a cytochrome P450 molecule; recovering said cells from said culture and suspending said cells in a high salt buffer; lysing said cells and removing cell debris to provide a high-salt lysate; adding to said lysate a detergent to provide a high-salt-detergent lysate; and recovering said P450 from said lysate. The method provides yields of P450 proteins suitable for crystallization.
... |
| Edible phosphoprotein film | 20060225610 | 20061012 |
| The invention provides a film comprising a phosphoprotein preparation, wherein the phosphoprotein preparation has been obtained by partially cross linking a partial hydrolysate of casein or a caseinate, a source of one or more physiologically acceptable cations, and a plasticizer. The film is preferably edible and substantially soluble. In particularly preferred embodiments, the source of one or more physiologically acceptable cations comprises natural milk calcium phosphate, and the plasticizer is glycerol.
... |
| Separation of contaminants from streptococcus pneumoniae polysaccharide by ph manipulation | 20060228381 | 20061012 |
| A process for reducing the protein content and preserving the capsular polysaccharide content in a complex cellular Streptococcus pneumoniae lysate broth prior to purification is described. Utilizing pH reduction after cellular lysis has resulted in a purified polysaccharide that consistently meets the protein specification, and higher recovery yields of polysaccharide during the purification process.
... |
| Oral and dental hygiene product | 20060222602 | 20061005 |
| An oral and dental hygiene product comprising a) a composite material containing poorly water-soluble calcium salts in the form of nanoparticulate primary particles which are between 5 and 150 nm long and have a cross-section of between 2 and 50 nm, and protein constituents selected from proteins, protein hydrolysates and protein hydrolysate derivatives, and b) between 0.1 and 9 wt. % of a cleaning agent, in relation to the total weight of the product. The inventive oral and dental hygiene product ensures an effective and long-lasting remineralization of the surface of the tooth, and a protective cleaning action of the cleaning or polishing agent.
... |
| Method for classifying a microorganism in a biological sample | 20060216780 | 20060928 |
| The invention provides a method using a hemocyte preparation, for example, Limulus amebocyte lysate, for detecting in a single assay the presence of at least one of a Gram negative bacterium, a Gram positive bacterium, and a fungus in a sample of interest. The method exploits the differential reactivity of Gram negative bacteria, Gram positive bacteria, and fungi with the hemocyte preparation to produce measurable changes in a property, for example, an optical property, of the mixture. Because the Gram negative bacteria, Gram positive bacteria and fungi each produce different changes in a given property, for example, an optical property, it is possible to classify the type of microorganism present in the sample of interest.
... |
| Ace inhibitory peptides from plant materials | 20060217318 | 20060928 |
| Improved processes are provided for preparing ACE inhibitory peptide containing hydrolysates from a plant material such as a seed meal or flour. In one embodiment, the seed meal or flour is extracted with an organic solvent prior to digestion. Also provided are ACE inhibitory peptides Val-Ser-Val and Phe-Leu.
... |
| Primer for heat-curable silicone elastomers | 20060207723 | 20060921 |
| A primer composition for silicone rubbers, in particular for addition-crosslinking silicone rubbers, comprises a tetraalkoxysilane and/or partial hydrolysate thereof, a metal salt, alkoxide, or chelate and/or partial hydrolysate thereof, a silicone resin, and from 50-95% by weight of solvent. The primer provides excellent adhesion between silicone rubber and numerous substrates.
... |
